马小丽教授指出："全国名中医继承仲景情志病思想，以半夏厚朴汤、栀子厚朴汤为基础方，拟定八味除烦汤，更适用于青少年、职场人群、老年人群、躯 体共病、发热性疾病患者人群。并且，为更好地造福更多抑郁焦虑患者，在八味除烦汤基础上创新转化研发出解郁除烦胶囊。"她表示，解郁除烦胶囊具有 多通道作用及良好的抗抑郁焦虑效果，且临床安全性更高，可作为新的治疗选择。 随后，马小丽教授在报告中介绍了多项解郁除烦胶囊治疗抑郁症的科学研究。"动物行为学研究显示，解郁除烦胶囊可能通过调节中枢神经中单胺类神经递 质水平NA、DN、5-HT发挥抗抑郁作用。一项随机、双盲、双模拟、多中心，样本量达560例的临床研究结果显示，对于主要证候为气郁痰阻、郁火内扰证 患者，解郁除烦胶囊可显著降低汉密顿焦虑量表（HAMA）评分，改善轻中度抑郁症患者抑郁焦虑状态、缓解躯体症状，且不增加不良反应发生率。解郁 除烦联合多元化有氧运动的临床研究显示，可提升青少年抑郁症整体疗效，减弱抑郁人格倾向、精神病态人格倾向，转变患者疾病应对方式。此外，临床研 究表明，解郁除烦胶囊不良反应发生率与安慰剂相当，明显低于氟西汀，安全性良好。" 近年来，随着中医药传承创新发展，在 ...

Core Viewpoint - The conference focused on the relationship between depression and insomnia, highlighting the importance of integrated treatment approaches using both traditional Chinese medicine and Western medicine to improve patient outcomes [1][2][4]. Group 1: Conference Overview - The "Chronic Disease Prevention and Treatment in China" conference was held on June 21, combining online and offline formats across Changsha, Wuhan, and Guangzhou, attracting hundreds of experts in mental health [1]. - Professor Zhang Honggeng presented a report on the understanding of "depression and insomnia" from both Chinese and Western medical perspectives, emphasizing the clinical effectiveness of innovative Chinese herbal medicines [1][3]. Group 2: Relationship Between Depression and Insomnia - Depression is characterized by persistent low mood lasting at least two weeks, while insomnia involves difficulty in falling or maintaining sleep for 2-3 weeks, both of which are interrelated [2]. - Approximately 40%-90% of depression patients experience insomnia symptoms, and 71.7% of those treated with antidepressants still have residual insomnia symptoms [2]. - Insomnia increases the risk of developing depression by 183%, anxiety disorders by 223%, and suicide risk by 67%, indicating a bidirectional relationship between the two conditions [2]. Group 3: Treatment Approaches - The conference highlighted the unique advantages of traditional Chinese medicine in identifying and treating depression and insomnia through personalized treatment plans [2][4]. - Innovative Chinese herbal medicines such as "Jieyu Chufan Capsule" and "Yishen Yangxin Anshen Tablet" were discussed for their significant clinical applications in treating different types of depression and insomnia [4]. - The "Jieyu Chufan Capsule" is effective for patients with symptoms like dizziness, chest tightness, and anxiety, while the "Yishen Yangxin Anshen Tablet" is recommended for patients with insomnia due to deficiency syndromes [4]. Group 4: Integration of Treatment Methods - The necessity of combining traditional Chinese and Western medicine for treating depression and insomnia was emphasized, as this approach can enhance treatment efficacy and reduce side effects [4].

"五一"假期里，有些青少年看似在享受休闲时光，实则暗藏心理隐忧。他们可能会有这些变化：原本活 泼的孩子变得沉默寡言，整天躲在房间里不愿与人交流；平时喜欢的兴趣爱好突然失去吸引力，对游 戏、追剧都提不起精神；作息变得紊乱，要么失眠熬夜，要么过度嗜睡，甚至出现食欲明显下降或暴饮 暴食的情况。这些看似"假期综合征"的表现，有可能是抑郁情绪的萌芽。 青少年抑郁之所以隐蔽，是因为其表现往往与成人不同。他们可能不会直接诉说"我很抑郁"，通常是以 身体不适为信号，如长期头痛、胃痛却查不出器质性病变；或者以行为问题呈现，如突然变得叛逆、厌 学、沉迷网络。家长要关注这些现象，帮助孩子驱散心里的"阴霾"。 认识假期背后的心理压力源 青少年抑郁问题近年来逐渐受到关注，尤其在假期这样特殊的时间节点，青少年的心理状态更值得留 意。本文就带大家深入了解"青少年抑郁"这一话题，让我们借助"五一"假期开启守护孩子心理健康之 旅。 关注青少年抑郁的隐蔽信号 五一守护计划：给青少年心灵真正放个假 在"五一"假期，家长可以尝试这些方式帮助孩子放松心灵。首先，减少对成绩的过度评判，转而关注孩 子的努力过程。例如，与其追问"考了多少分"，不如倾听"今 ...

Core Viewpoint - Yiling Pharmaceutical reported a net loss for 2024 due to revenue reduction from expiring respiratory products and increased inventory impairment, but maintains high R&D investment levels, with over 900 million yuan allocated, representing 13.94% of revenue, which is leading in the industry [1][5]. R&D Investment - Yiling Pharmaceutical has a strong R&D capability based on its unique theory of network disease, which has led to a nearly 25-fold increase in R&D investment since 2008 [2]. - The company continues to maintain high R&D investment levels, with 900 million yuan in 2024, ranking among the top in the industry [5]. Product Development and Pipeline - The company has 17 patented new drugs, with 11 included in the national medical insurance directory and 5 in the national essential drug list [5]. - Yiling Pharmaceutical has ongoing registration applications for two innovative traditional Chinese medicine products and three chemical drug products, enhancing its product pipeline [6]. Market Performance - Yiling Pharmaceutical's respiratory and cardiovascular products lead their respective markets, with Lianhua Qingwen capturing 24.36% of the cold medicine market in public healthcare [7]. - The company’s core cardiovascular products hold a combined market share of 17.69% in the public healthcare sector [7]. New Growth Areas - The company is expanding into the health and wellness sector, with products targeting blood lipid regulation, sleep improvement, and blood sugar control [8]. - Yiling Pharmaceutical's OTC product Baizi Bujin Capsule is highlighted as a potential new pillar product, supported by extensive evidence from clinical studies [8].